Legit Tirzepatide

What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained | Tirzepatide

The short version

Tirzepatide is a drug injected once a week under the skin. It belongs to a class called incretin mimetics — drugs that copy the action of hormones your gut releases after eating. What makes tirzepatide different from older drugs in this family is that it activates two of those hormone receptors instead of one: the GIP receptor and the GLP-1 receptor. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both hormones your intestine releases when food arrives, and both signal the pancreas to release insulin. Tirzepatide mimics both at once. The practical result in trials was larger reductions in blood sugar and body weight than drugs that target only the GLP-1 receptor. It is FDA-approved as a prescription medicine for type 2 diabetes, for chronic weight management in obesity or overweight with complications, and for obstructive sleep apnea in adults with obesity. It is a tirzepatide peptide — a 39-amino-acid synthetic molecule with a fatty-acid arm that keeps it in the body long enough for once-weekly dosing.

What is tirzepatide? Structure and classification

Tirzepatide (INN: tirzepatide; development code LY3298176; CAS 2023788-19-2) is a 39-amino-acid synthetic acylated peptide built on the native GIP hormone backbone. A C20 fatty-diacid arm (eicosanedioic acid) is attached via a glutamic-acid linker and two AEEA spacer units to a lysine side chain. That fatty-acid modification confers high albumin affinity, which extends the half-life to approximately 5 days and enables once-weekly subcutaneous dosing. Molecular formula: C225H348N48O68. Molecular weight: 4,813.53 Da. ATC code: A10BX16.

The tirzepatide peptide is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first approved agent in this class. It is also called a 'twincretin' or 'dual incretin mimetic' in the literature [1].

It is not an endogenous peptide. The native incretin hormones it mimics — GIP and GLP-1 — are gut-derived, but tirzepatide itself is a synthetic analogue engineered from the GIP backbone.

Tirzepatide mechanism of action: why two receptors matter

Both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) are expressed across multiple tissues beyond the pancreas: liver, muscle, adipose tissue, central nervous system, heart, immune system, and kidney [11]. Engaging both receptors with a single molecule produces a richer signal than targeting GLP-1R alone.

In vitro receptor studies found that tirzepatide is an imbalanced dual agonist — it engages the GIP receptor more fully than the GLP-1 receptor. It also shows biased GLP-1 receptor signalling, favouring cAMP generation over beta-arrestin recruitment and producing weaker GLP-1 receptor internalisation than native GLP-1 [12]. In primary islet experiments, the biased agonism contributed to enhanced insulin secretion compared with reference agonists.

The net effect: glucose-dependent insulin secretion is increased through both receptor pathways simultaneously; glucagon (a hormone that raises blood glucose) is suppressed; gastric emptying slows, reducing post-meal glucose spikes; and central appetite signalling dampens food intake. The dual mechanism is the proposed basis for the larger weight-reduction effect relative to selective GLP-1 receptor agonism seen in head-to-head trials [2][4].

Tirzepatide peptide signalling is glucose-dependent — it stimulates insulin secretion primarily when blood glucose is elevated. This is the property that keeps hypoglycaemia risk low on the drug alone (the risk rises when combined with insulin or a sulfonylurea [6]).

FDA approval: what is tirzepatide approved for?

Three approvals have been granted by the U.S. FDA:

  1. Type 2 diabetes mellitus (May 2022): adjunct to diet and exercise in adults. The approval rested on the SURPASS programme, a multi-trial phase 3 programme that included direct head-to-head comparison with semaglutide in SURPASS-2 [2] and combination with basal insulin in SURPASS-5 [13].
  1. Chronic weight management (November 2023): in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition. The approval rested on SURMOUNT-1 and -2 results. SURMOUNT-1 enrolled 2,539 participants without diabetes and demonstrated -20.9% body weight at 72 weeks at the highest dose versus -3.1% with placebo [3].
  1. Moderate-to-severe obstructive sleep apnea in adults with obesity: based on SURMOUNT-OSA data showing reduction in the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep) alongside substantial weight reduction [14].

The FDA prescribing information notes that tirzepatide is not approved for type 1 diabetes. The weight-loss indication is an extension of the approved programme; it is not an off-label use for the approved obese/overweight population with a complication [6].

The prescribing information carries a boxed warning — a thyroid C-cell tumour risk observed in rodents during the drug class development. This signal has not been established in humans. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [6].

Tirzepatide peptide: the compound in context

Before tirzepatide, the incretin class was built around GLP-1 receptor agonists — molecules that mimic only GLP-1. That generation produced significant glycaemic and weight benefits but left the GIP receptor untouched. Tirzepatide was the first compound to demonstrate that adding GIP agonism to a GLP-1 mimetic could produce meaningfully better outcomes in large randomised trials rather than in theory alone.

The SURMOUNT-5 head-to-head trial (n=751, 72 weeks) confirmed the magnitude of that advantage in obesity without diabetes: tirzepatide at maximum tolerated dose produced -20.2% body weight versus -13.7% with semaglutide at maximum tolerated dose — a 6.5 percentage point difference [4]. In type 2 diabetes, SURPASS-2 showed superior HbA1c reduction at all three doses of tirzepatide versus semaglutide 1 mg [2].

The mechanism for that advantage — why dual receptor engagement outperforms single receptor engagement at comparable doses — continues to be studied. The imbalanced GIPR-favouring agonism and biased GLP-1R signalling documented in the Willard et al. 2020 in vitro characterisation are the most detailed molecular accounting available [12].